Literature DB >> 20180777

Obesity and arterial compliance alterations.

Alexander M Seifalian1, Theodosios D Filippatos, Jatin Joshi, Dimitri P Mikhailidis.   

Abstract

Obesity is associated with increased cardiovascular disease (CVD) risk, especially when excess body fat is distributed preferentially within the abdominal region. Obese subjects usually have increased arterial stiffness compared with non-obese subjects of similar age. The factors associated with increased arterial stiffness in obesity include endothelial dysfunction (decreased nitric oxide bioavailability), impaired smooth muscle cell function, insulin resistance, as well as elevated cholesterol and C-peptide levels. Furthermore, visceral fat, the adipose tissue-related renin-angiotensin-aldosterone system and hyperleptinaemia contribute to the obesity-associated impaired arterial compliance. Weight loss improves CVD risk factors and arterial compliance. Because increased arterial stiffness is a marker of CVD risk these findings support the concept that the presence of obesity has vascular implications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180777     DOI: 10.2174/157016110790886956

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  21 in total

Review 1.  Impact of maternal obesity on fetal programming of cardiovascular disease.

Authors:  Victoria H J Roberts; Antonio E Frias; Kevin L Grove
Journal:  Physiology (Bethesda)       Date:  2015-05

2.  Does chronic kidney disease modify the association between body mass index and cardiovascular disease risk factors.

Authors:  Nisha Bansal; Eric Vittinghoff; Laura Plantinga; Chi-Yuan Hsu
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

3.  Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients.

Authors:  Erhan Tatar; Meltem Sezis Demirci; Fatih Kircelli; Ozkan Gungor; Mehmet Nuri Turan; Ebru Sevinc Ok; Gulay Asci; Mehmet Ozkahya; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

Review 4.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 5.  Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links.

Authors:  Lanfranco D'Elia; Pasquale Strazzullo
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-11-02

6.  Removal of interscapular brown adipose tissue increases aortic stiffness despite normal systemic glucose metabolism in mice.

Authors:  Zachary I Grunewald; Nathan C Winn; Michelle L Gastecki; Makenzie L Woodford; James R Ball; Sarah A Hansen; Harold S Sacks; Victoria J Vieira-Potter; Jaume Padilla
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-12-20       Impact factor: 3.619

Review 7.  The role of perivascular adipose tissue in vasoconstriction, arterial stiffness, and aneurysm.

Authors:  Luis Villacorta; Lin Chang
Journal:  Horm Mol Biol Clin Investig       Date:  2015-02

Review 8.  Dapagliflozin in patients with type 2 diabetes mellitus.

Authors:  Theodosios D Filippatos; Evangelos N Liberopoulos; Moses S Elisaf
Journal:  Ther Adv Endocrinol Metab       Date:  2015-02       Impact factor: 3.565

Review 9.  Cellular mechanisms underlying obesity-induced arterial stiffness.

Authors:  Annayya R Aroor; Guanghong Jia; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-22       Impact factor: 3.619

10.  Association of impaired arterial wall properties with the presence of coronary artery disease in patients with abdominal aortic aneurysms.

Authors:  Pinelopi Rafouli-Stergiou; Ignatios Ikonomidis; Niki Katsiki; Nikolaos P E Kadoglou; Stefanos Vlachos; John Thymis; John Parissis; Konstantinos G Moulakakis; John D Kakisis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.